Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
AstraZeneca Purchase Aims At Triglycerides
by Lisa M. Jarvis
June 3, 2013
| A version of this story appeared in
Volume 91, Issue 22
In its latest bid to bolster its late-stage pipeline, AstraZeneca is acquiring Princeton, N.J.-based Omthera Pharmaceuticals. With the deal, AstraZeneca gains Epanova, an omega-3 free-fatty-acid composition in development to lower triglyceride levels. Omthera plans to file a New Drug Application for Epanova this year. AstraZeneca expects to pursue other indications, including a fixed-dose combination with its cholesterol-lowering drug Crestor. AstraZeneca will pay about $260 million for Omthera and could pay another $120 million in milestones related to the launch of Epanova.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter